A detailed history of Jane Street Group, LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 318,760 shares of XERS stock, worth $1.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
318,760
Previous 347,592 8.29%
Holding current value
$1.07 Million
Previous $782,000 16.11%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.06 - $2.96 $59,393 - $85,342
-28,832 Reduced 8.29%
318,760 $908,000
Q2 2024

Aug 14, 2024

BUY
$1.7 - $2.45 $199,977 - $288,203
117,634 Added 51.15%
347,592 $782,000
Q1 2024

May 15, 2024

BUY
$2.04 - $3.22 $13,002 - $20,524
6,374 Added 2.85%
229,958 $508,000
Q4 2023

Feb 14, 2024

BUY
$1.47 - $2.36 $117,570 - $188,752
79,980 Added 55.69%
223,584 $525,000
Q3 2023

Nov 14, 2023

BUY
$1.8 - $2.69 $30,940 - $46,238
17,189 Added 13.6%
143,604 $267,000
Q2 2023

Aug 14, 2023

SELL
$1.82 - $2.98 $17,120 - $28,032
-9,407 Reduced 6.93%
126,415 $331,000
Q1 2023

May 15, 2023

SELL
$1.03 - $1.63 $47,112 - $74,556
-45,740 Reduced 25.19%
135,822 $221,000
Q4 2022

Feb 14, 2023

BUY
$1.14 - $1.65 $72,918 - $105,540
63,964 Added 54.39%
181,562 $241,000
Q3 2022

Nov 14, 2022

SELL
$1.37 - $1.93 $203,716 - $286,987
-148,698 Reduced 55.84%
117,598 $183,000
Q3 2022

Nov 14, 2022

SELL
$1.37 - $1.93 $203,716 - $286,987
-148,698 Reduced 55.84%
117,598 $183,000
Q2 2022

Aug 16, 2022

SELL
$1.48 - $2.64 $290,942 - $518,979
-196,583 Reduced 42.47%
266,296 $410,000
Q1 2022

May 17, 2022

BUY
$2.0 - $2.87 $698,938 - $1 Million
349,469 Added 308.15%
462,879 $1.19 Million
Q4 2021

Feb 15, 2022

BUY
$1.8 - $2.93 $204,138 - $332,291
113,410 New
113,410 $332,000

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $458M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.